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Abstract: 
                   
Peptide deformylase (PDF) is a metalloproteinase and executes an essential step in the 
maturation of proteins in eubacteria, by removing the formyl group from the N-terminal methionine 
residue of ribosome-synthesized polypeptides1. This process is crucial for bacterial survival 
because mature proteins do not retain N-formyl-methionine, and all known N-terminal peptidases 
cannot utilize formylated peptides as substrate2. Thus, inhibition of PDF is essential to obstruct 
the bacterial protein maturation process. Antibiotics based on PDF inhibition have the potential to 
provide the much needed antibacterial activity against most of the major drug-resistant 
pathogens3. This study comprises of an implementation of in-silico techniques to validate and 
map the features of the respective active site of PDF from Leptospira interrogans. Our analysis 
consolidates PDF as a promising target for developing novel alternatives as well as indicates 
superior affinity of current therapeutic agents towards it. This consequently provides a new insight 
for leptospirosis treatment. 
 
Keywords: Peptide deformylase, Leptospira interrogans, Leptospirosis. CADD, Docking, Genetic 
algorithm, Grid, Grip, antibiotics, anti-infective. 
 
Introduction: 
 
Leptospirosis is a worldwide zoonotic infectious disease transmitted by animals to humans. 
Severe leptospirosis may result in hospitalization and about 5% of the patients die. It has a 
greater incidence in tropical regions and has now been identified as one of the emerging 
infectious diseases exemplified by large recent outbreaks in Nicaragua, Brazil, India, Southeast 
Asia and United States4, 5, 6. It is of ubiquitous distribution, caused by infection with pathogenic 
Leptospira interrogans. These spirochaetes are transmitted to man usually either by direct or 
indirect contact with the urine of the infected animal. The clinical presentation of the disease is 
biphasic, with the acute or septicemic phase lasting about a week, followed by immune phase, 
characterized by antibody production and excretion of leptospires in urine 4 .The spectrum of 
human disease caused by leptospires is extremely wide, ranging from sub-clinical infection to a 
severe syndrome of multi-organ infection with high mortality. In vitro and animal experiments have 
demonstrated that leptospires are sensitive to a wide range of antibiotics and unfortunately limited 
resources of antibiotics are currently used in prophylaxis of leptospirosis. Antibiotics need to be 
administered as soon as leptospirosis is suspected and preferably before the fifth day after the 
onset of illness. The benefit of antibiotics after the fifth day of the disease is controversial. 
However, most clinicians treat leptospirosis with antibiotics regardless of the time of onset of the 
illness. Antibiotics that are used commonly in the treatment of leptospirosis are penicillin (high 
doses) intravenously given in severe cases, Doxycycline, Amoxicillin, Ampicillin, Erythromycin are 
given orally in less severe cases 2.Treatment of severe leptospirosis (organism localized in 
tissues) is still unclear3. Therefore, it is important to propose antileptospiral drugs. Availability of 
complete genome sequence of certain Leptospira interrogans serovar has opened enormous 
opportunities for identifying potential drug targets by computational analysis.  
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Peptide deformylase (PDF) is one of the promising targets discovered for developing new 
antibiotics and its conformational states have been characterized 2 .It is a metalloproteinase and 
executes an essential step in the maturation of proteins in eubacteria, by removing the formyl 
group from the N-terminal methionine residue of ribosome-synthesized polypeptides1. This 
process is crucial for bacterial survival because mature proteins do not retain N-formyl-
methionine, and all known N-terminal peptidases cannot utilize formylated peptides as substrate7. 
Thus, inhibition of PDF, by interfering with the bacterial protein maturation process, is providing a 
vital target for developing a promising anti-infective therapeutic intervention without interfering 
with eukaryotic metabolism 5. In this study, PDF is used as a Receptor molecule and few 
conventional leptospirosis drugs including Actinonin, a specific inhibitor of PDF were used as 
Ligand molecules8. Phytochemical that have antimicrobial properties and capable of acting 
against infections and diseases of humans and animals can also act as an inhibitor 9, 10. 
 Picrorrhiza kurroa Royle ex Benth (Family: Scrophulariaceae) is a perennial herb, 
growing primarily in the north-west Himalayan mountains. Earlier studies have reported that, 
rhizomes and roots of this plant are widely used for the treatment of a range of liver diseases 11, 
12. Interestingly, leptospirosis affects liver and in severe cases it is responsible for liver damages 
so the possibility of the active phytochemicals of this plant being effective to cure this disease can 
not be ruled out. Kutkin is the active principal of Picrorhiza kurroa and is comprised of kutkoside 
and the iridoid glycoside picrosides-1, 2, and 3.The active constituents responsible for the 
medicinal properties of P. kurroa are mainly picroside-1 and picroside –2. 13.  
This analysis is an attempt of verifying the conventional drugs and introducing a new phytodrug 
by using docking approaches to facilitate the valuable insights for leptospirosis treatment. The 
information generated can contribute in understanding, and development of further strategies in 
treatment of leptospirosis. 
 
Methodology: 
 
Selection of Receptor molecules & Ligands 
               Initially, existence of different types of proteins was found out using Structural 
Classification of Proteins (SCOP) of Leptospira interrogans ser. Lai 56601. The protein, Peptide 
deformylase was selected as a target based on prior research publication2.  The Crystal Structure 
of PDF from Leptospira Interrogans (LiPDF) at pH 7.5 was obtained from RCSB Protein Data 
Bank (1sv2) 2 known to be a stable dimmer2. Other Penicillin binding proteins as well as 
Tetracycline repressor protein was referred from the RCSB Protein Data Bank. The respective 
accession numbers are 1qme14 and 2o7o15.   The mentioned targets were preferred to perform 
comparative binding analysis with the specific drug molecules and leads. On the basis of current 
therapy for management of leptospirosis, Penicillin-G, Ampicillin, Amoxicillin and Doxycycline 
were selected for analysis. In addition to these Beta lactum and Tetracycline class of drugs, 
actinonin-the known inhibitor of PDF8 and picroside analogues (phytochemicals) were also given 
contemplation as potential lead for prophylaxis of leptospirosis (figure 1). Intermolecular 
interactions of these ligands were optimized to attain a local minimum energy structure using 
force fields like AMBER, MMFF, UFF and Dreiding. 
 
Identification of Cavities 
The cavities in the receptor were mapped to assign an appropriate active site, the basic feature 
used to map the cavities were the surface mapping of the receptor and identifying the geometric 
voids as well as scaling the void for its hydrophobic characteristics. Hence all the cavities that are 
present in PDF receptor are identified and ranked based on their size and hydrophobic surface 
area as depicted in table 1. 
Considering the dimensions and hydrophobic surface area, Cavity-1 was found to be the best 
void as an active site. Similarly active sites on Penicillin binding receptor and Tetracycline 
repressor protein was also characterised for performing docking analysis. 
 
Docking Approaches 
Molecular interactions play a key role in all biological reactions. Drugs are either mimicking or 
mitigating the effect of natural ligands binding to the receptor by exerting the pharmacological 
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reactions. Computational methods are used to understand this mode of binding of ligands to their 
receptors which is called as Molecular Docking. It is an attempt to find out the “best” binding 
between different a set of molecules: a receptor and a ligand16.  Subsequently two basic scoring 
functions, Systematic Method and probabilistic approach were used for docking analysis. 
Systematic Method: This method emploies rigid docking protocol and explore binding mode of 
ligand exhaustively over a grid in the cavity. For this method we have used following two 
approaches  
a. GRIP: GRIP docking employees the PLP scoring function in a novel way for fast and 
accurate capturing of lignad receptor interactions in the active site of proteins. For this 
purpose, VLife-MDS incorporates the Piecewise Linear Pairwise Potential (PLP) scoring 
function in GRIP docking method that includes interactions like hydrogen bonding, 
repulsions and dispersion. 
b. GRID: In this approach, the atomic details of the ligand and the receptor binding site are 
simulated explicitly, while the other bulk portions of system are represented as grids 17.    
Stochastic Method: In this probabilistic approach we have used Genetic Algorithm (GA) which is 
based on stochastic principles. This GA based method takes flexibility of ligand and receptor in to 
consideration so that supply of conformers of ligands is not required. It also generates a wide 
population of initial poses that ultimately evolve into optimal binding mode. 
 
Results and Discussion: 
 
Penicillin and Tetracycline class of drugs show binding interactions only with their indigenous 
receptors akin to penicillin binding receptor and Tetracycline repressor protein respectively. The 
approach taken in this paper is to compare the binding interactions of these existing drugs with 
other receptor sites to validate the affinity for interpreting novel mechanism of action. 
At present we have carried out a comparative docking analysis of the existing drug molecules 
used in leptospirosis treatment on the selected active site referred in table 1.  Astoundingly, 
results indicated better docking scores illustrated in (table 3 and 4).  
 
As per the discussed approach, primarily pharmacophoric mapping on the predicted active site 
was carried out. The Active site of Peptide Deformylase Protein (PDF) was validated using MDS 
tools, to calculate force fields and molecular mechanics.  
The pharmcophoric site and their characteristics are shown in Figure 2.  
The active site constitutes of following residues of cavity-1: 
CHAIN-A: MET37A, PHE38A, MET41A, ARG42A, ALA44A, GLU45A, GLY46A, VAL47A, 
VAL62A, VAL63A, GLY64A, SER65A, GLU66A, ASP67A, ASN68A, PRO75A, ASP76A, VAL77A, 
PRO78A, GLU79A, ARG80A, ILE81A, TYR136A, LYS137A,  
CHAIN-B: THR27B, LYS38B, GLU29B, PHE30B, LYS31B, LYS32B, LEU33B, ILE34B, ARG35B, 
PHE38B, ARG42B, ILE60B, VAL61B, VAL62B, VAL63B, GLU79B, ARG80B, ILE81B, ILE82B, 
LEU83B, MET122B, ASP123B, GLU124B, LYS125B, ASN127B. 
 
Docking of Doxycycline ligand with PDF receptor has shown good score of all i.e.-4.550790 
Kcal/mol by GA Method and -5.049634 Kcal/mol by GRID Method, which has been observed tobe 
similar to the activity on the native site demonstrated in table1, as -3.733443 Kcal/mol and -
5.209398 Kcal/mol respectively. On the other hand beta-lactum antibiotics also demonstrated 
superior binding affinity towards PDF receptor as compared to the results in table1,  the native 
receptor binding of Penicillin-G is -2.707211 Kcal/mol and -4.825700 Kcal/mol as compared to -
4.155 Kcal/mol and -4.801 Kcal/mol with PDF using scoring function GA and Grid dock. Similarly 
Amoxicillin and ampicillin also illustrated admirable binding affinity with PDF, there respective 
scores with native receptor using GA and Grid based docking is -0.77 Kcal/mol and -4.71 
Kcal/mol approximately, while with PDF they exhibited -4.4 Kcal/mol and -4.8 Kcal/mol 
approximately. This comparative binding clearly indicates that the justified antibiotics show 
considerably strong affinity towards PDF receptor, which may signify a vital role in formation of 
inhibitory complex for treating infections like leptosprosis.  
In our approach we have also identified indigenous analogues Picroside 1 and 2 from plant origin 
which are also used to treat leptosprosis. For these molecules, we have made an attempt to 
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verify and locate their affinity towards PDF. The basic docking analysis using GA and Grid 
functions (table 2.) indicated a promising prospect for these molecules tobe used as a second line 
drug. The docking results clearly indicated comparable analysis with actinonin which is a specific 
binding ligand on PDF. Docking features of actinonin using GA and Grid gave a score of -3.33 
Kcal/mol and -3.88 Kcal/mol respectively while picroside-1 proved to be slightly more specific by 
demonstrating the scores -3.78 Kcal/mol and -4.28 Kcal/mol. On the other hand pecroside-2 
analogue proved to be quiet similar to actinonin as far as binding scores are concerned. 
 
To further emphasis on the docking functions and for checking the binding scores of the 
respective drug analogues on PDF, they were subjected to a specific Piecewise Linear Pairwise 
Potential (PLP) scoring function using a specifically designed batch process docking function 
called as Grip docking. The Grip docking is a fast scoring algorithm which can be operated in two 
formats, fast scoring and Exhaustive scoring functions. Table 4, demonstrates the results of the 
drugs exposed to grip docking.  Here, in the batch docking of Actinonin in fast scoring method 
displayed a score of -40.714548 Kcal/mol at optimised ligand pose 13(Figure 4 a.), while in the 
batch exhaustive-Grip function Picroside-1 and Picroside-2 with PDF receptor have shown good 
score as compared to other ligands in the batch, Picroside-1 and 2 exhibited a dock -70.399479 
Kcal/mol at optimised pose 5 and -71.767968 Kcal/mol at optimised pose 21 respectively by 
Exhaustive-GRIP Methods. 
 
Hydrophobic interactions are one of the major interactive forces in ligand recognition and binding. 
Electrostatic interactions like Van der Waals and charge interactions are also required in fitting a 
ligand into a specific cavity of a receptor. Taking into consideration the above results (Table 3, 4), 
following interactions are exhibited by all ligands. All results mentioned here after are major 
common interfaces occurred during diverse docking studies. 
 
Actinonin: 
Actinonin showed following interactions with the residues of active site, 
Hydrophobic interactions: with GLU66A, ASP76A, PRO78A, LYS31B, ILE81B, GLU124B, 
LYS32B, ILE34B, ARG35B, VAL77A, and PHE38B.  
Van der Waals interactions: with GLU66A, PRO78A, VAL77A, GLU124B, LYS31B, ILE34B, 
ARG35B, ILE81B, PHE38B and  
Charge interactions: with SER65A, ASP76A, LYS31B, LYS32B, and ARG35B.  
Detail about the residue and ligand atoms are reported in table 5 and figure 5. 
Doxycycline: 
Doxycycline interacted very well and showed following interactions with the residues of active 
site, 
Hydrophobic interactions: with PRO75A, ASP76A, PRO78A, LYS31B, ILE34B, ILE81B, and 
GLU124B.  
Van der Waals interactions: with PRO75A, ASP76A, PRO78A, ILE25B, PHE30B, LYS31B, 
ILE34B, ARG35B, PHE38B, GLU79B, ARG80B, GLU124B, ILE81B and GLN26B. 
Charge interactions: with ASP76A, LYS31B. 
Detail about the residue and ligand atoms are reported in table 6 and figure 6. 
Penicillin-G: 
Penicillin-G showed following interactions with the residues of active site, 
Hydrophobic interactions: with ASP76A, PRO78A, LYS31B, PRO75A, and LYS28B.  
Van der Waals interactions: with ASP76A, PRO78A, LYS31B, GLU66A, VAL77A, LYS28B, 
GLU124B, ILE25B, GLN26B, ILE34B and ILE81B. 
Charge interactions: with ASP76A, LYS31B, SER65A and LYS31B. 
Detail about the residue and ligand atoms are reported in table 7 and figure 7a. 
Amoxicillin: 
Amoxicillin showed following interactions with the residues of active site, 
Hydrophobic interactions: with ASP76A, ILE25B, GLN26B, LYS31B, ILE34B, ARG35B, PHE38B, 
GLU124B, and GLU66A.  
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Van der Waals interactions: with PRO75A, ASP76A, GLN26B, ILE25B, THR27B, LYS31B, 
ARG80A, LYS137A, PHE30B, ILE34B, ARG35B, ARG42B, ILE81B, GLU124B, HOH48, HOH51 
and ASP67A.  
Charge interactions: with ASP76A, LYS28B, ARG80A and LYS31B.  
Detail about the residue and ligand atoms are reported in table 8 and figure 7b. 
Ampicillin: 
Ampicillin of the same group was interacted as follows, 
Hydrophobic interactions: with GLU66A, ASP76A, VAL77A, PRO78A, LYS28B, ILE25B, 
ARG35B, GLY64A, SER65A, GLU79A, and PRO75A.  
Van der Waals interactions: with GLU66A, ASP76A, VAL77A, PRO78A, THR27B, LYS31B, 
ILE25B, ILE34B, ARG35B, ILE81B, GLU124B, GLY64A, SER65A, ASP76A, GLU79A, LYS32B 
Charge interactions: with ASP76A, LYS31B, SER65A. 
Detail about the residue and ligand atoms are reported in table 9 and figure 7c. 
Picroside-1: 
Picroside-1 being a phytochemical displayed good interactions and are as follows, 
Hydrophobic interactions: with ASP76A, ILE25B, LYS31B, GLU124B, GLU66A, PRO78A, 
GLN26B, LYS32B, ILE34B, and ARG35B.  
Van der Waals interactions: with ASP76A, PRO78A, ILE25B, PHE30B, LYS31B, GLU66A, 
VAL77A, ILE34B, ILE81B, GLN26B, GLU124B, ARG35B and LYS32B.  
Charge interactions: with ASP76A, LYS31B, LYS32B, ARG35B and SER65A.  
Detail about the residue and ligand atoms are reported in table 10 and figure 7a. 
Picroside-2: 
The another analogue of picroside exhibited following interactions, 
Hydrophobic interactions: with ILE34B, ARG80B, ILE81B, ASP123B, GLU124B, ASP76A, 
PRO78A, LYS28B, LYS31B, LYS32B, ILE34B, ARG35B, and LYS125B.  
Van der Waals interactions: with PRO78A, LYS137A, ILE34B, GLU79B, ARG80B, ILE81B, 
TRP121B, ASP123B, HOH48, GLU66A, ASP76A, GLN26B, THR27B, LYS28B, LYS31B, 
PRO78A, GLU66A, GLU79A, LYS32B, ILE34B, ARG35B, HOH48.  
Charge interactions: with ARG80B, LYS28B, LYS31B, ASP76A, LYS32B, ARG35B and 
LYS125B. 
Detail about the residue and ligand atoms are reported in table 11 and figure 7b. 
 
Conclusion: 
The present analysis indicates that traditional drugs used in the treatment of leptospirosis can 
also form a complex with PDF, with a significant binding efficiency. This swot builds a perceptive 
focus towards these drugs, that when administrated during the treatment of leptospirosis may 
block PDF along with their specific indigenous receptors. This creates a strong hypothesis that 
the combine effect of the complex formation with PDF and the inhibitory complex formed with 
respective receptors may alleviate the concerned prophylaxis. Hence PDF may become a 
prospective target for inhibition of pathogenic leptospira bacteria and may unlock a strong 
initiative in developing novel ligands which are specific towards it. Moreover the current drugs 
used can under go Me-Too specifications to improve its specificity towards PDF.  In addition to 
this, Picroside analogues from Picrorrhiza kurroa have given away a promising corollary for 
developing a novel phytodrug. To strengthen the current investigation, further evidences both in 
vitro and in vivo are needed so as to use this approach effectively for prophylactic treatment of 
laptospirosis.  
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Table 1
No. Cavity Geometri
c surface 
area (Å)
Hydropho
bic 
Surface 
Area (Å)
1 Cavity# 1 5388 3265.15
2 Cavity# 2 3636 4332.23
3 Cavity# 3 1755 1766.27
4 Cavity# 4 1748 1343
5 Cavity# 5 1709 2081.5
6 Cavity# 6 1354 1382.49
Table 1: Illustrates the geometric voids identified in the receptor and designates it hydrophobic c
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characteristics 
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Table 2.
GA 
Method
GRID
(Kcal/mol
)
Method
(Kcal/mol
)
Penicillin 
binding 
Receptor
Penicillin-
G
-2.707211 -4.8257
(1qme) Amoxicillin -0.775389 -4.715156
Ampicillin -0.757542 -4.802315
Tetracycli
ne 
Represso
r
(2o7o)
Table 2: Native receptor-ligand docking scores by GA and GRID methods
No. Protein Ligand 
Molecule
1
2 Doxycyclin
e
-3.733443 -5.209398
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Table 3.
GA 
Method
GRID 
Method
(Kcal/mol
)
(Kcal/mol
)
1 Actinonin -3.33537 -3.880482
2 Penicillin 
G
-4.155875 -4.801342
3 Doxycycli
ne
-4.55079 -5.049634
4 Ampicillin -4.457447 -4.799671
5 Amoxicillin -4.117719 -4.736773
6 Picroside-
1
-3.789607 -4.282135
7 Picroside-
2
-3.396345 -3.915923
Table 3: Docking scores by GA and GRID methods on PDF.
No. Ligand 
Molecule
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Table 4
GRIP Exhaustiv
e
Method GRIP
(Kcal/mol
)
Method
(Kcal/mol
)
1 Actinonin -40.71455 13 -60.40166 11
2 Penicillin 
G
-30.07556 9 n.s n.s
3 Doxycyclin
e
-32.302 19 n.s n.s
4 Ampicillin -30.81348 5 -60.65366 14
5 Amoxicillin -29.89646 21 n.s n.s
6 Picroside-
1
n.s n.s -70.39948 5
7 Picroside-
2
-31.6659 1 -71.76797 21
Table 4: Docking scores by GRIP and EX-GRIP methods on PDF 
n.s:- results not shown by the particular molecule. 
Pose- It is an optimised structure which illustrates better binding with the receptor.
No. Ligand 
Molecule
Pose Pose
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Table 5
Actinonin
RESIDUE Hydro VDW Charge Hydro VDW Charge Hydro VDW
r-485C, r-485C,
SER65A l-2790N l-2782C
d-4.894 d-4.147
r-489C r-489C r-492C r-493C r-493C r-489C
GLU66A l-2787C l-2787C l-2783C l-2776C l-2776C l-2791O
d-3.868 d-3.868 d-3.146 d-3.941 d-3.941 d-3.25
r-570C r-568C r-568C r-567C r-570C r-570C r-570C
ASP76A l-2787C l-2778N l-2790N l-2776C l-2775C l-2776C l-2774C
d-2.72 d-3.323 d-4.739 d-2.828 d-3.14 d-3.701 d-3.46
r-582C r-578N r-582C r-579C
PRO78A l-2776C-d-
3.498
l-2791O l-2776C l-2787C
d-3.242 d-3.109 d-3.914
r-1577C r-1575C r-1577C r-1575C r-1577C
LYS31B l-2776C l-2776C-d-
4.952
l-2771C l-2776C l-2787C
d-4.339 d-3.523 d-4.403 d-4.218
r-1958C r-1958C r-1958C
ILE81B l-2772C l-2769C l-2786C
d-4.154 d-4.198 d-4.064
r-2300C r-2303O r-2297C r-2301C
GLU124B l-2771C l-2770O l-2771C l-2786C
d-3.176 d-3.067 d-4.456 d-4.832
Table 5: Exhibits details about the interactions occurred between Actinonin and receptor with res
GA GRID GRIP FAST
r-residue atom number, l-ligand atom number, d- distance in Ao
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Charge Hydro VDW Charge
r-485C,
l-2791O
d-4.455
r-493C r-496O
l-2772C l-2772C
d-4.016 d-3.398
r-568C r-570C r-570C r-568C
l-2787C l-2776C l-2789O l-2776C
d-4.57 d-1.967 d-3.394 d-4.181
r-582C r-579C
l-2769C l-2769C
d-3.171 d-3.474
r-1577C r-1576O r-1575C
l-2771C l-2769C l-2769C
d-4.106 d-3.279 d-3.543
r-1958C
l-2784C
d-4.662
pective receptor.
GRIP EXHAUSTIVE
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Table 6.
Doxycyline
Hydro VDW Charge Hydro Hydro VDW
r-563C r-561C r-563C
l-2793C l-2793C l-2793C
d-3.15 d-3.441 d-4.937
r-570C r-566N r-568C r-570C r-570C r-570C
l-2785C l-2786C l-2793C l-2780C l-2782C l-2782C
d-3.526 d-3.361 d-3.766 d-4.498 d-3.672 d-3.672
r-584C r-584C r-584C
l-2779C l-2779C l-2780C
d-3.868 d-3.868 d-4.673
r-1569C r-1569C
l-2795O l-2795O
d-3.316 d-3.316
r-1577C r-1576O r-1575C r-1577C r-1577C
l-2777C l-2795O l-2776O l-2770C l-2768C
d-4.346 d-3.114 d-3.651 d-3.848 d-3.565
r-1597C r-1595C r-1597C
l-2780C l-2776O l-2770C
d-4.977 d-3.58 d-4.428
Table 6: Exhibits details about the interactions occurred between Doxycycline and with respectiv
Residue GA GRID GRIP FAST
VDW
ASP76A 
PRO75A
PRO78A r-583C
l-2795O
d-3.503
PHE30B
LYS31B r-1576O
l-2795O
d-3.375
r-residue atom number, l-ligand atom number, d- distance in Ao
ILE34B r-1594O
l-2796N
d-3.147
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ve receptor.
Charge
r-568C
l-2784C
d-4.99
r-1575C
l-2769O
d-4.165
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Table 7.
Penicillin-G
Hydro VDW Charge Hydro VDW Charge Hydro VDW
r-492C r-496O r-488N
l-2787C l-2771O l-2780C
d-4.811 d-3.173 d-3.388
r-570C r-566N r-568C r-570C r-570C r-568C r-570C r-570C
l-2768C l-2771O l-2767O l-2776C l-2782C l-2782C l-2786C l-2775O
d-4.217 d-3.078 d-4.358 d-4.496 d-3.733 d-4.980 d-3.606 d-3.427
r-579C r-574O r-571N
l-2785C l-2787C l-2781C
d-3.786 d-3.432 d-3.638
r-584C r-579C r-579C r-578N
l-2768C l-2767O l-2787C l-2787C
d-4.868 d-3.331 d-2.950 d-3.286
r-1549C r-1552C r-1550C
l-2768C l-2771O l-2767O
d-4.733 d-3.259 d-3.851
r-1577C r-1577C r-1575C r-1577C r-1577C r-1575C
l-2786C l-2785C l-2787C l-2768C l-2772C l-2786C
d-2.353 d-3.527 d-4.655 d-3.319 d-3.424 d-3.744
Table 7:  Reveals particulars about the interactions take place between Penicillin-G and with respective
Residue GA GRID GRIP FAST
ASP76A
GLU66A
PRO78A
VAL77A
r-residue atom number, l-ligand atom number, d- distance in Ao.
LYS31B
LYS28B.
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Charge
r-568C
l -2781C
d-4.105
e receptor.
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Table 8.
Amoxicillin:
Hydro VDW Charge Hydro VDW Charge Hydro VDW
r-563C
l-2778C
d-3.778
r-570C r-568C r-570C r-570C
l-2776C l-2776C l-2782C l-2782C
d-4.127 d-4.428 d-3.672 d-3.672
r-601N r-604N r-601N
l-2779C l-2778C l-2779C
d-4.637 d-3.39 d-4.637
r-1530C r-1527O
l-2788C l-2788C
d-4.139 d-3.248
r-1533C r-1532N r-1535O
l-2788C l-2765O l-2794C
d-4.711 d-3.417 d-3.489
r-1577C r-1577C r-1575C r-1574C r-1575C r-1577C r-1577C
l-2768C l-2767O l-2773N l-2771O l-2773N l-2770C l-2768C
d-3.899 d-3.232 d-3.697 d-3.23 d-3.697 d-3.848 d-3.565
Table 8:  Reveals particulars about the interactions take place between Amoxicillin and with resp
RESIDUE GA GRID GRIP FAST
PRO75A
ASP76A
ARG80A
ILE25B
LYS31B
r-residue atom number, l-ligand atom number, d- distance in Ao.
GLN26B
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Charge
r-568C
l-2784C
d-4.99
r-1575C
l-2769O
d-4.165
pective receptor.
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Table 9.
Hydro VDW Charge Hydro VDW Charge Hydro VDW
r-480C r-481C
l-2788C l-2788C
d-3.838 d-3.526
r-484C r-486O
l-2788C l-2787C
d-3.197 d-3.432
r-493C r-493C r-492C r-494C
l-2768C l-2767O l-2787C l-2787C
d-4.243 d-3.295 d-1.738 d-3.433
r-570C r-569O r-568C r-570C r-568C r-568C r-570C
l-2768C l-2773N l-2773N l-2788C l-2788C l-2788C l-2775O
d-3.797 d-3.244 d-3.177 d-4.247 d-4.303 d-4.43 d-3.253
r-572C r-571N r-572C r-572C r-574O
l-2776C l-2773N l-2788C l-2788C l-2786C
d-4.357 d-3.247 d-4.815 d-3.562 d-3.269
r-584C r-578N r-582C r-582C r-579C r-578N
l-2776C l-2783N l-2787C l-2767O l-2788C l-2788C
d-2.958 d-3.224 d-3.057 d-3.464 d-3.604 d-3.372
r-590C r-592O
l-2768C l-2767O
d-4.479 d-3.418
r-1530C r-1526C
l-2776C l-2783N
d-4.292 d-3.725
r-1577C r-1577C r-1577C r-1575C r-1577C r-1576O
l-2787C l-2786C l-2787C l-2765O l-2776C l-2771O
d-2.741 d-3.5 d-3.746 d-4.279 d-4.839 d-3.211
Table 9:  Reveals particulars about the interactions take place between Ampicillin and with respe
RESIDUE GA GRID GRIP FAST
GLY64A
SER65A
GLU66A
ASP76A
VAL77A
PRO78A
GLU79A
r-residue atom number, l-ligand atom number, d- distance in Ao.
Ampicillin:
LYS31B
ILE25B
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Charge Hydro VDW Charge
r-485C r-483N r-485C
l-2787C l-2781C l-2780C
d-2.956 d-3.282 d-3.652
r-488N
l-2781C
d-3.323
r-568C r-570C r-569O
l-2782C l-2788C l-2785S
d-4.243 d-4.318 d-3.401
r-574O
l-2780C
d-3.427
r-579C r-578N
l-2776C l-2775O
d-4.303 d-3.472
r-590C
l-2779C
d-3.491
r-1575C r-1577C r-1576O r-1575C
l-2773N l-2776C l-2773N l-2783N
d-3.883 d-3.12 d-3.249 d-3.108
ective receptor.
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Table 10.
Picroside-1:
Hydro VDW Charge Hydro VDW Charge Hydro
r-493C r-493C r-492C
l-2780C l-2785O l-2765C
d-4.599 d-3.45 d-4.45
r-570C r-569O r-568C r-570C r-570C
l-2766C l-2802H l-2796C l-2782C l-2766C
d-4.828 d-3.196 d-4.832 d-3.969 d-4.711
r-582C r-579C r-583C r-582C
l-2799C l-2784C l-2787O l-2775C
d-3.511 d-3.894 d-3.567 d-3.421
r-1530C r-1530C r-1530C r-1527O
l-2780C l-2786O l-2765C l-2769C
d-4.348 d-3.518 d-3.902 d-3.493
r-1533C r-1535O
l-2767C l-2776O
d-2.848 d-3.124
r-1577C r-1573N r-1575C r-1577C r-1577C r-1575C r-1575C
l-2784C l-2787O l-2787O l-2779C l-2792O l-2788C l-2775C
d-3.157 d-3.231 d-3.678 d-3.113 d-3.307 d-4.642 d-3.196
Table 10:  Reveals particulars about the interactions take place between Pricroside and with res
RESIDUE GA GRID GRI
ASP76A
GLU66A
ILE25B
PRO78A
LYS31B
r-residue atom number, l-ligand atom number, d- distance in Ao.
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VDW Charge
r-496O
l-2801H
d-3.128
r-566N r-568C
l-2793C l-2771C
d-3.542 d-4.542
r-582C
l-2800H
d-3.196
r-1576O
l-2800H
d-3.186
pective receptor.
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Table 11.
Picroside-2:
Hydro VDW Charge Hydro VDW Charge Hydro VDW
r-570C r-570C r-570C r-570C
l-2777C l-2774C l-2780C l-2780C
d-3.098 d-3.475 d-3.544 d-3.544
r-579C r-583C r-583C r-583C
l-2768C l-2799C l-2770C l-2799C
d-3.744 d-4.213 d-3.644 d-4.213
r-1550C r-1549C r-1549C
l-2773C l-2773C l-2771O
d-4.213 d-3.36 d-3.483
r-1577C r-1576O r-1575C r-1577C r-1549C
l-2779C l-2770C l-2770C l-2773C l-2771O
d-4.601 d-3.345 d-4.062 d-2.982 d-3.483
r-1946C r-1947N r-1947N
l-2795C l-2798O l-2798O
d-2.926 d-3.345 d-3.345
r-1958C r-1952C
l-2773C l-2799C
d-4.455 d-3.47
r-2309C r-2309C r-2307C
l-2799C l-2800O l-2799C
d-2.822 d-3.431 d-4.34
GRIP FASTRESIDUE GA GRID
PRO78A
ASP76A
LYS31B
LYS28B
ARG80B
ILE81B
r-residue atom number, l-ligand atom number, d- distance in Ao.
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